IDEAYA Biosciences Appoints Joshua Bleharski, Ph.D., as Chief Financial Officer

IDEAYA Biosciences has announced the appointment of Joshua Bleharski, Ph.D., as its new Chief Financial Officer. With nearly 17 years of experience at J.P. Morgan’s Healthcare Investment Banking group, Dr. Bleharski has advised on financing and strategic transactions totaling over $65 billion. His deep expertise in corporate finance and investment strategy will be instrumental as IDEAYA advances its robust oncology pipeline. CEO Yujiro S. Hata emphasized that Dr. Bleharski’s leadership will help accelerate IDEAYA’s mission to develop precision medicine solutions for cancer treatment.

Expressing enthusiasm for his new role, Dr. Bleharski highlighted IDEAYA’s six clinical-stage programs and three preclinical programs targeting solid tumors. He looks forward to collaborating with the team to drive financial and strategic growth. His background as a scientist, coupled with extensive investment banking experience, uniquely positions him to guide IDEAYA’s financial strategy through its next phase of expansion. His appointment signals the company’s commitment to innovation and long-term value creation in precision oncology.